President Donald Trump has announced the launch of TrumpRx.gov, a new federal prescription drug platform the White House says will immediately cut the cost of many popular medications by as much as 80 percent for millions of Americans.
The initiative marks one of the most ambitious efforts yet to tackle high out-of-pocket drug costs in the United States and is being hailed by administration officials as a historic victory for patients who have long paid more than those in other developed nations.
The program is built around a network of “Most-Favored-Nation” pricing agreements between the U.S. government and participating pharmaceutical companies. Under the deals, drugmakers agree to offer Americans the same or lower prices than those charged to patients abroad — a significant shift after decades of higher domestic pricing.
“Last night, President Trump delivered on a core promise to the American people — ending the era where Americans pay far more for the same drugs than patients overseas,” the White House said in a statement. “TrumpRx means lower prices at the pharmacy counter, starting now.”
Trump framed the announcement as a long-awaited breakthrough. “For years, politicians from both parties have promised to bring down prescription drug prices and make health care more affordable, but they all failed,” Trump said Thursday at the White House. “It’s the biggest thing to happen in health care, I think, in many, many decades.”
Unlike Medicare or private pharmacy benefit programs, TrumpRx does not sell drugs directly. Instead, the website connects patients with manufacturers who have signed onto the pricing agreements, providing access to direct-purchase discounts, coupons, or special offers that bypass traditional pharmacy middlemen. Users can search by drug name and see the best available pricing, with the platform updated daily.
The White House said the rollout targets high-cost brand-name medications that place the greatest strain on household budgets — especially GLP-1 diabetes and weight-loss drugs and fertility treatments.
Under the new pricing structure:
- Ozempic drops from about $1,028 to roughly $350 per month, with some doses available for as low as $199.
- Wegovy injections fall from $1,349 to similar pricing, while its oral pill version can cost as little as $149, depending on dosage.
- Zepbound, another GLP-1 drug, declines from $1,088 to an average of $346, with some doses near $299.
The White House said the price cuts represent up to 80% savings compared to typical U.S. pharmacy costs. Trump administration officials estimate millions of Americans using these medications could collectively save billions of dollars annually under the new model.
Fertility treatments — which often aren’t covered by insurance and can cost families thousands per cycle — are also seeing sharp reductions.
- Gonal-F, a leading fertility drug, now costs as low as $168 per pen.
- Cetrotide falls from $316 to $22.50.
- Ovidrel drops from $251 to $84.
“These are real savings that people will see right away,” a senior White House health official said. “This isn’t theoretical — these are price cuts negotiated directly with manufacturers.”
Trump urged Congress to act swiftly to make the reforms permanent. He called on lawmakers to pass his proposed “Great Healthcare Plan,” which would codify Most-Favored-Nation pricing into law, require full price transparency, and allow TrumpRx purchases to be integrated with health insurance coverage.
“For too long, the middlemen and special interests have driven up costs and rigged the system,” Trump said. “With TrumpRx, we’re putting patients — not the lobbyists — first.”
The Department of Health and Human Services said more than 40 manufacturers have already joined the TrumpRx platform, and more are expected in the coming weeks. Officials said the administration will prioritize adding high-impact treatments for chronic illnesses such as heart disease, asthma, cancer, and autoimmune disorders later this year.
Industry analysts said the program could represent a turning point if major pharmaceutical firms comply with the pricing benchmarks. But they also cautioned that the model’s success will depend on sustained political support and cooperation from Congress.
